본문으로 바로가기

의료진 소개

이민종 의사

이민종 교수

소화기내과(소화기센터), 소화기센터 관심의료진 등록

전문 진료 분야

만성 B형간염, 알코올성 간질환, 비알코올성 지방간, 간세포암. 간경변증. 급성간염, 만성 C형간염

진료 일정

학력사항

  • 서울대학교 의과대학 박사
  • 서울대학교 의과대학 석사
  • 서울대학교 의과대학 졸업

교육 및 연구경력

  • 2020-현재  | 이대서울병원 소화기내과 임상조교수
  • 2016-2020  | 강원대학교병원 소화기내과 임상조교수
  • 2016  | 서울대학교병원 강남센터 소화기내과 진료교수
  • 2014-2015  | 서울대학교병원 소화기내과 전임의
  • 2010-2014  | 서울대학교병원 내과 전공의
  • 2008-2009  | 서울대학교병원 인턴

기타 학술 관련 경력

  • 2019-현재  | 대한간암학회 보험위원회 위원
  • 2018-현재  | 대한간학회 간행위원회 위원
  • 2018-현재  | 대한간암학회 간행위원회 위원
  • 2018-2019  | 대한간학회 섭외위원회 위원

논문

  •  Aspirin and the Risk of Hepatocellular Carcinoma Development in Patients with Alcoholic Cirrhosis.  Medicine (Baltimore). 2020-02. 
  •   Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department A multicenter study.  CLINICAL AND MOLECULAR HEPATOLOGY. 2022, v.28 no.3 , 540-552. 
  •  Outcome of Intermittent Thoracentesis versus Pigtail Catheter Drainage for Hepatic Hydrothorax.  JOURNAL OF CLINICAL MEDICINE. 2022, v.11 no.23 , 7221-7221. 
  •  Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study.  DIABETES & METABOLISM. 2022, v.48 no.5 , 101362-101362. 
  •  Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.  LIVER INTERNATIONAL. 2023, v.43 no.3 , 608-625. 
  •  Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease.  CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2023, v.21 no.2 , 358-369. 
  •  Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.  LIVER INTERNATIONAL. 2023, v.43 no.3, 608-625. 
  •  Is Partial Splenic Embolization a Good Option to Prevent Cirrhotic Complications in the Long Term?.  Journal of Korean Medical Science. 2019-08. 
  •  Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.  Journal of hepatology. 2018-11. 
  •  Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis.  Medicine (Baltimore). 2018-11. 
  •  The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment.  Journal of Clinical Gastroenterology. 2018-11. 
  •  Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification.  Gut Liver. 2018-09. 
  •  Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.  PLoS One. 2018-07. 
  •  Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro.  Oncology Letters. 2018-06. 
  •  Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.  Hepatology. 2017-11. 
  •  A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?.  Digestive and Liver Disease. 2017-11. 
  •  Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients.  PLoS One. 2017-06. 
  •  Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.  World Journal of Biological Chemistry. 2017-05. 
  •  3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.  PLoS One. 2017-03. 
  •  Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.  Clinical and Molecular Hepatology. 2017-03. 
  •  Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area.  PLoS One. 2017-01. 
  •  Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients.  PLoS One. 2017-01. 
  •  Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm: A matched case-control comparative analysis.  Medicine (Baltimore). 2016-08. 
  •  Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.  PLoS One. 2016-05. 
  •  17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.  Biochemical and Biophysical Research Communications. 2016-05. 
  •  A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.  British Journal of Cancer. 2015-12. 
  •  Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.  Molecular Medicine Reports. 2015-12. 
  •  Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.  Liver International. 2015-12. 
  •   Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43.  Acta Pharmaceutica Sinica B. 2015-11. 
  •  Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.  Liver International. 2015-08. 
  •  Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in korean patients with chronic hepatitis B.  Gastroenterology Research and Practice. 2015-02. 
  •  Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.  Antimicrobial Agents and Chemotherapy. 2015-02. 
  •  JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.  Molecular Medicine Reports. 2015-01. 
  •  CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis.  Liver International. 2015-01. 
  •  Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.  Journal of Viral Hepatitis. 2014-12. 
  •  Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.  PLoS One. 2014-11. 
  •   Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.  Antimicrobial Agents and Chemotherapy. 2014-11. 
  •  Long-term oncologic outcomes of endoscopic stenting as a bridge to surgery for malignant colonic obstruction: comparison with emergency surgery.  Surgical Endoscopy. 2014-09. 
  •  Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.  PLoS One. 2014-07. 
  •  Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?.  PLoS One. 2014-08. 
  •  Computed tomographic colonography is valuable for post-treatment evaluation and screening of hidden colorectal cancer in patients with cryptogenic pyogenic liver abscess.  Digestion. 2014-08. 
  •  Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer.  Gut Liver. 2014-05. 
  •  High-sensitivity C-reactive protein level is an independent predictor of poor prognosis in cirrhotic patients with spontaneous bacterial peritonitis.  J Clin Gastroenterol. 2014-05. 
  •  Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.  Antimicrobial Agents and Chemotherapy. 2014-03. 
  •  Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization.  PLoS One. 2014-03. 
  •  Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.  Antimicrobial Agents and Chemotherapy. 2013-12. 
  •  Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study.  Clinical Cancer Research. 2013-08. 
  •  The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.  Korean Journal of Radiology. 2009-11. 
  •  FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.  Korean Journal of Radiology. 2007-05. 
  •  Expression of mucins and cytokeratins in primary carcinomas of the digestive system.  Modern Pathology . 2003-05.